11
Participants
Start Date
March 8, 2021
Primary Completion Date
August 23, 2022
Study Completion Date
April 24, 2023
Pegloticase
Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
Methotrexate (MTX)
Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
Altoona Center for Clinical Research, Duncansville
The Center for Rheumatology and Bone Research, Wheaton
Napa Research, Pompano Beach
Life Clinical Trials, Margate
IRIS Research and Development, LLC, Plantation
GCP Clinical Research, LLC, Tampa
Biopharma Informatic, LLC, Houston
Arizona Arthritis and Rheumatology Associates, Mesa
Arizona Arthritis and Rheumatology Associates, Glendale
Arizona Arthritis and Rheumatology Associates, Flagstaff
Providence St. John's Health Clinic, Santa Monica
East Bay Rheumatology Medical Group, San Leandro
Western Washington Arthritis Clinic, Bothell
University of Alabama at Birmingham (UAB) - Center for Education & Research on Therapeutics of Musculoskeletal Disorders, Birmingham
University of Colorado Anschutz Medical Campus, Aurora
Lead Sponsor
Amgen
INDUSTRY